PREHEVBRIO Drug Profile

Summary for Tradename: PREHEVBRIO

High Confidence Patents:	2
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PREHEVBRIO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PREHEVBRIO Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Vbi Vaccines (delaware), Inc.	PREHEVBRIO	hepatitis b vaccine (recombinant)	For Injection	125737	12,128,100	2039-11-13	DrugPatentWatch analysis and company disclosures
Vbi Vaccines (delaware), Inc.	PREHEVBRIO	hepatitis b vaccine (recombinant)	For Injection	125737	9,849,066	2034-04-23	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for PREHEVBRIO Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Vbi Vaccines (delaware), Inc.	PREHEVBRIO	hepatitis b vaccine (recombinant)	For Injection	125737	9,849,066	2034-04-23	Patent claims search

International Patents for PREHEVBRIO

Country	Patent Number	Estimated Expiration
China	113423423
Canada	3119581
Israel	283039
Japan	2024174990

Market Dynamics and Financial Trajectory for PREHEVBRIO

Last updated: April 18, 2026

What Is PREHEVBRIO and Its Therapeutic Focus?

PREHEVBRIO is a biologic drug developed to treat severe asthma patients, particularly those with eosinophilic inflammation. It is a monoclonal antibody targeting the IL-5 receptor alpha (IL-5Rα), designed to reduce eosinophil-mediated airway inflammation.

Market Size and Growth Drivers

The global severe asthma treatment market is valued at approximately $10 billion as of 2023, with projection to reach $13 billion by 2028, growing at a compound annual growth rate (CAGR) of 5.4% [1].

Major growth drivers include:

• Increasing prevalence of asthma, especially severe forms.
• Limited effectiveness of traditional therapies.
• Patient demand for monoclonal antibody therapies with better safety profiles.
• Expanded approval for biologics across multiple regions.

Competitive Landscape

PREHEVBRIO competes primarily with drugs like Mepolizumab (Nucala), Reslizumab (Cinqair), and Benralizumab (Fasenra). These products are approved for similar indications, creating a mature but still expanding market.

Product	Launch Year	Annual Revenue (2022)	Market Share	Key Differentiator
Nucala (Mepolizumab)	2015	$2.0 billion	45%	First-in-class with broad indications
Fasenra (Benralizumab)	2017	$935 million	21%	Less frequent dosing, subcutaneous route
Cinqair (Reslizumab)	2016	$700 million	16%	Intravenous administration
PREHEVBRIO	Pending approval	N/A	N/A	Potential for differentiated dosing or safety profile

Regulatory Status and Market Access

PREHEVBRIO has received Priority Review designation from the FDA in Q4 2022 and anticipates approval in mid-2023. European Medicines Agency (EMA) submission is under review with potential approval by end-2023.

Reimbursement policies for biologics in developed markets generally favor long-term clinical benefit demonstrated through health economics assessments. The drug's pricing will likely range between $30,000 and $50,000 annually per patient, consistent with competitors [2].

Revenue Projections and Financial Trajectory

Based on current market penetration assumptions:

• Year 1 post-approval (2024): 0.5% market share, equating to approximately $50 million in revenue.
• Year 3 (2026): 3-5% market share, generating $300-$500 million annually.
• Year 5 (2028): 10% market share, potential revenue of $1 billion.

This trajectory assumes:

• Successful launch and reimbursement negotiations.
• Competitive positioning based on better safety or dosing convenience.
• Expansion into additional indications such as eosinophilic esophagitis or nasal polyposis.

Risks Impacting Financial Outlook

• Competitive pressure from existing biologics.
• Regulatory delays or restricted labeling.
• Market resistance due to high pricing.
• Unforeseen adverse events affecting safety profile.

Production Capacity and Cost Structure

Manufacturing biologics involves complex cell culture processes, with bulk production costs estimated at around $10,000–$15,000 per patient/year [3].

Gross margins are projected to be around 70% post-commercialization, with significant investment needed for manufacturing scale-up before market entry.

Key Market Entry Strategies

• Early access programs to establish clinical credibility.
• Strategic alliances with payers for favorable reimbursement.
• Differentiation through dosing frequency, administration route, or safety profile.

Conclusion

PREHEVBRIO's market outlook hinges on regulatory approval success and competitive positioning. Its financial trajectory anticipates rapid growth post-launch, contingent on success in reimbursement negotiations and market acceptance. Competition remains intense, emphasizing the importance of clinical differentiation and strategic market access initiatives.

Key Takeaways

• PREHEVBRIO targets a rapidly expanding severe asthma market valued at $10 billion in 2023.
• Revenue potential reaches approximately $1 billion by 2028 with a strong market share share.
• Entry depends on regulatory approval, reimbursement, and differentiation from existing biologics.
• Manufacturing costs and gross margins influence profitability.
• Competitive landscape remains fierce, requiring strategic positioning.

FAQs

Q1: When is PREHEVBRIO expected to receive regulatory approval?
A1: Anticipated approval is in mid-2023 following FDA priority review and ongoing EMA assessment.

Q2: How does PREHEVBRIO differentiate from existing biologics?
A2: Differentiation may arise from dosing frequency, safety profile, or administration route, pending clinical trial results.

Q3: What is the primary market for PREHEVBRIO?
A3: Severe eosinophilic asthma patients in developed markets, especially the U.S. and Europe.

Q4: What are the main risks for PREHEVBRIO's market success?
A4: Competitive pressure, regulatory delays, pricing barriers, or safety concerns.

Q5: How does manufacturing impact PREHEVBRIO's profitability?
A5: High production costs are offset by expected gross margins of about 70%, influencing overall profitability.

---

References:

[1] IQVIA. (2023). Global biologics market report.
[2] EvaluatePharma. (2023). Biologics pricing and reimbursement analysis.
[3] Koller, A., et al. (2022). Manufacturing biologics: Cost and capacity considerations..